Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)— a Study of the European Leukemianet-Based MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 4264.

https://doi.org/10.1182/blood.V130.Suppl_1.4264.4264

Published: 2017

Journal Articles

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Blood (2017) 130 (Supplement 1): 425.

https://doi.org/10.1182/blood.V130.Suppl_1.425.425

Published: 2017

Journal Articles

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Marlijn Hoeks, MD, Saskia Langemeijer, MD PhD, Louise De Swart, MD, Tim Bagguley, Corine van Marrewijk, PhD, David Bowen, MD PhD, Jaroslav Cermak, Eva Hellstrom-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, Marian G.J. Van Kraaij, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic J Culligan, Marta Krejci, MD PhD, Jackie Droste, PhD, Alexandra Smith, PhD, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2016) 128 (22): 4327.

https://doi.org/10.1182/blood.V128.22.4327.4327

Published: 2016

Journal Articles

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Louise De Swart, MD, Chloé Reiniers, Tim Bagguley, David Bowen, MD PhD, Jaroslav Cermak, MD PhD, Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Argiris Symeonidis, MD PhD, Gerwin Huls, MD PhD, Panagiotis Panagiotidis, Hege Garelius, MD, Dominic Culligan, Marta Krejci, Corine van Marrewijk, Jackie Droste, PhD, Alexandra Smith, Dorine W. Swinkels, MD PhD, Theo de Witte, MD PhD

Blood (2015) 126 (23): 2865.

https://doi.org/10.1182/blood.V126.23.2865.2865

Published: 2015

Journal Articles

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry

Blood (2013) 122 (21): 2770.

https://doi.org/10.1182/blood.V122.21.2770.2770

Published: 2013

Journal Articles

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

Louise de Swart, Alex Smith, Pierre Fenaux, Guillermo Sanz, Eva Hellstrom-Lindberg, Argyris Symeonidis, Jaroslav Cermak, Ulrich Germing, MD, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, Krzysztof Madry, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, David Bowen, Theo de Witte

Blood (2012) 120 (21): 3830.

https://doi.org/10.1182/blood.V120.21.3830.3830

Published: 2012

Journal Articles

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

Raphael Itzykson, Alex Smith, Theo M. de Witte, Jackie Droste, Reinhard Stauder, Argyris Symeonidis, Eva Hellstrom-Lindberg, Guillermo Sanz, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Mette Skov-Holm, Ulrich Germing, MD, Marius MacKenzie, Odile Beyne-Rauzy, MD, PhD, Luca Malcovati, David Bowen, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 700.

https://doi.org/10.1182/blood.V120.21.700.700

Published: 2012

Journal Articles

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, MD, PhD, David Bowen, Guillermo Sanz, MD, Eva Hellström-Lindberg, Argyris Symeonidis, Jaroslav Cermak, MD, PhD, Ulrich Germing, MD, Reinhard Stauder, MD, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, MD, Mette Skov Holm, MD, PhD, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, Theo de Witte, MD, PhD

Blood (2011) 118 (21): 2775.

https://doi.org/10.1182/blood.V118.21.2775.2775

Published: 2011

Journal Articles

Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry

Reinhard Stauder, Alex Smith, Theo de Witte, Jackie Droste, Pierre Fenaux, MD, PhD, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo F Sanz, MD, PhD, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Odile Beyne-Rauzy, Luca Malcovati, David Bowen

Blood (2010) 116 (21): 3999.

https://doi.org/10.1182/blood.V116.21.3999.3999

Published: 2010

Journal Articles

The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients

David Bowen, Alex Smith, Jackie Droste, Pierre Fenaux, MD, PhD, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo F Sanz, MD, PhD, Jaroslav Cermak, MD, PhD, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, Odile Beyne-Rauzy, Luca Malcovati, Theo de Witte

Blood (2010) 116 (21): 1867.

https://doi.org/10.1182/blood.V116.21.1867.1867

Published: 2010

Journal Articles

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

Louise de Swart, Alex Smith, Pierre Fenaux, Argyris Symeonidis, Eva Hellström-Lindberg, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Odile Beyne-Rauzy, Luca Malcovati, Reinhard Stauder, Jackie Droste, David Bowen, Theo de Witte

Blood (2010) 116 (21): 2917.

https://doi.org/10.1182/blood.V116.21.2917.2917

Published: 2010

Journal Articles

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.

T. M. de Witte, Alex Smith, Jackie Droste, Pierre Fenaux, Argyris Symeonidis, Eva Hellstrom-Lindberg, MD, PhD, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, MD, Odile Beyne Rauzy, David T. Bowen, MD

Blood (2009) 114 (22): 3811.

https://doi.org/10.1182/blood.V114.22.3811.3811

Published: 2009

NARROW

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)— a Study of the European Leukemianet-Based MDS (EUMDS) Registry

Impact of Treatment with Iron Chelation Therapy in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry

Elevated Labile Plasma Iron Levels (LPI) and Increased Oxidative Stress Are Associated with Red Blood Cell Transfusions in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Subtitle: from the European Leukemianet MDS Registry

Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry

The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only